ASH 2022 | Using CRISPR/Cas9 gene editing to generate NKG2A-knockout CD33-CAR-NK cells for the treatment of AML
Evelyn Ullrich, MD, PhD, Goethe University Frankfurt, Frankfurt, Germany, summarizes recent work adapting CAR-NK cells for the treatment of acute myeloid leukemia (AML). Prof. Ullrich first explains the advantages of NK cells over T cells, highlighting that NK cells do not induce graft-versus-host disease (GvHD), cytokine release syndrome (CRS), or neurotoxicity, and can be supplied by third-party donors. Prof. Ullrich then explains how CRISPR/Cas9 technology was used to generate primary CD33-expressing CAR-NK cells with NKG2A knockout, to overcome immunosuppressive effects mediated by HLA-E expression on malignant AML cells. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Honoraria; Phialogics: Honoraria.
